Judith Bryson, an executive with Pozen, is the new vice president for clinical development at Serenex.

Serenex is developing drugs to treat cancer with two products undergoing clinical trials.

Bryson will be responsible for clinical development at Serenex. The company is in the process of raising $35 million in additional venture capital, according to The Triangle Business Journal.

At Pozen, Bryson was vice president for clinical development. She has also worked for EMD Pharmaceuticals and at Glaxo Wellcome. At EMD she was global product leader for oncology.

"We are extremely pleased to have Judy join Serenex,” said Richard Kent, chief executive officer at Serenex. “She brings a wealth of senior level oncology clinical development experience and leadership to the company. We have a number of exciting and important oncology programs underway and Judy’s experience will be essential in moving them through the clinic.”

The lead product Serenex, SNX-1012, is targeted at patients with solid tumors. It is in Phase II clinical trials. A second drug candidate is expected to begin clinical trials in the second quarter.